Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.